Literature DB >> 6707650

Presynaptic nicotinic cholinergic receptors labeled by [3H]acetylcholine on catecholamine and serotonin axons in brain.

R D Schwartz, J Lehmann, K J Kellar.   

Abstract

Nicotinic cholinergic receptor binding sites labeled by [3H]acetylcholine were measured in the cerebral cortices, thalami, striata, and hypothalami of rats lesioned by intraventricular injection of either 6-hydroxydopamine or 5, 7-dihydroxytryptamine. In addition, [3H]acetylcholine binding sites were measured in the cerebral cortices of rats lesioned by injection of ibotenic acid into the nucleus basalis magnocellularis. [3H]Acetylcholine binding was significantly decreased in the striata and hypothalami of both 6-hydroxydopamine- and 5,7-dihydroxytryptamine-lesioned rats. There was no change in binding in the cortex or thalamus by either lesion. Ibotenic acid lesions of the nucleus basalis magnocellularis, which projects cholinergic axons to the cortex, did not alter [3H]acetylcholine binding. These results provide evidence for a presynaptic location of nicotinic cholinergic binding sites on catecholamine and serotonin axons in the striatum and hypothalamus.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6707650     DOI: 10.1111/j.1471-4159.1984.tb02818.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  35 in total

1.  Alterations in neocortical expression of nicotinic acetylcholine receptor mRNAs following unilateral lesions of the rat nucleus basalis magnocellularis.

Authors:  I Miyai; S Ueno; S Yorifuji; H Fujimura; S Tarui
Journal:  J Neural Transm Gen Sect       Date:  1990

Review 2.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

3.  Chronic nicotine treatment increases dopamine levels and reduces dopamine utilization in substantia nigra and in surviving forebrain dopamine nerve terminal systems after a partial di-mesencephalic hemitransection.

Authors:  K Fuxe; A M Janson; A Jansson; K Andersson; P Eneroth; L F Agnati
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-03       Impact factor: 3.000

Review 4.  Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.

Authors:  P A Newhouse; A Potter; E D Levin
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

5.  A microdialysis study of the effects of the nicotinic agonist RJR-2403 on cortical release of acetylcholine and biogenic amines.

Authors:  K L Summers; P Lippiello; E Giacobini
Journal:  Neurochem Res       Date:  1996-10       Impact factor: 3.996

Review 6.  Prefrontal neuromodulation by nicotinic receptors for cognitive processes.

Authors:  Renata dos Santos Coura; Sylvie Granon
Journal:  Psychopharmacology (Berl)       Date:  2012-01-18       Impact factor: 4.530

7.  Effects of acute intermittent exposure to cigarette smoke on hypothalamic and preoptic catecholamine nerve terminal systems and on neuroendocrine function in the diestrous rat.

Authors:  K Andersson; P Eneroth; K Fuxe; A Härfstrand
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-02       Impact factor: 3.000

8.  Effects of thalamic lesion on the bilateral regulation of serotoninergic transmission in rat basal ganglia.

Authors:  D Becquet; M Faudon; F Hery
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

9.  Purification and characterization of a nicotinic acetylcholine receptor from rat brain.

Authors:  P Whiting; J Lindstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

10.  Release of [3H]-noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]-dopamine release.

Authors:  P B Clarke; M Reuben
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.